Gains for new Medtronic boss

Medtronic posted quarterly earnings in line with analyst targets yesterday, as sales of its diabetes products, heart stents and other devices offset challenges for its important implantable heart and spine products. First-quarter net income was $821m (£497m) or 77 cents a share, compared with $830m, or 76 cents a share, a year ago, as new chief executive Omar Ishrak outlined his growth plans for the firm.